JAK3

eGenesis Appoints Eliezer Katz, M.D., FACS, as Chief Medical Officer

Retrieved on: 
Montag, April 4, 2022
Virology, Integris Health, Cell, Therapy, Drug development, Human, Degenerative disease, Manifest and latent functions and dysfunctions, LAM, Transplant, Consultant, Kidney, CMO, Inebilizumab, Medical Affairs Bureau, Horizon, Neuromyelitis optica spectrum disorder, Liver transplantation, Immune system, Industry, Pfizer, Knowledge, Gene editing, Technology, JAK3, Lymphangioleiomyomatosis, Acquisition, GLOBE, Drug, MedImmune, Policy, VP, Clinical trial, Organ transplantation, FDA, CRISPR, University, Patient, FACS, Pharmaceutical industry, Dentistry, Vaccine

CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs and cells, today announced the appointment of Eliezer Katz, M.D., FACS, as Chief Medical Officer (CMO).

Key Points: 
  • CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs and cells, today announced the appointment of Eliezer Katz, M.D., FACS, as Chief Medical Officer (CMO).
  • He oversaw the development of therapeutics to modulate the immune system in autoimmune diseases and organ transplantation.
  • eGenesis goal is to transform the field of transplantation by offering safe and effective organs and cells to patients in need.
  • eGenesis development pipeline includes lead programs for kidney and islet cell transplant as well as earlier-stage programs focused on other solid organs.

CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

Retrieved on: 
Dienstag, März 1, 2022
Janus, Hematology, TYK2, Pneumonia, JAK3, Mount Sinai, Population, HIV disease progression rates, Heart, Webcast, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Peripheral edema, BAT, Bleeding, Toxicity, Fever, Haematopoiesis, Diarrhea, Associate professor, ID, CTI, JAK1, Cytokine, CTIC, Nausea, FMS, Vera, Disease, BD, CD135, DRI, Food, CSF1R, Acquisition, FLT3, Ruxolitinib, Caregiver, Cytopenia, Skin, FDA, Primary myelofibrosis, Platelet, Nasdaq, BID, Thrombocytopenia, Patient, Anemia, Pacritinib, Icahn School of Medicine at Mount Sinai, Oncology, JAK2, Pharmaceutical industry, Medicine

The accelerated approval is based on efficacy results from the pivotal Phase 3 PERSIST-2 study of VONJO in patients with myelofibrosis (platelet counts less than or equal to 100 109/L).

Key Points: 
  • The accelerated approval is based on efficacy results from the pivotal Phase 3 PERSIST-2 study of VONJO in patients with myelofibrosis (platelet counts less than or equal to 100 109/L).
  • As part of the accelerated approval, CTI is required to describe a clinical benefit in a confirmatory trial.
  • CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

STAT Inhibitors Drug Pipeline Markets Research 2022: Insights About 60+ Companies and 60+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Dienstag, Februar 8, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Apoptosis, News, Nausea, Discovery, Daewoong Pharmaceutical, Jiangsu Hengrui Medicine, STAT3, III, STAT5, Protein, Hepatic stellate cell, STAT5B, Acquisition, II, Infection, Clinical trial, STAT1, JAK3, STAT6, STAT5A, JAK2, COVID, STAT inhibitors, Niclosamide, Therapy, Oxidative phosphorylation, JAK1, Tyrosine, Oligonucleotide, Signal, STAT, Vomiting, Fatigue, JAK, Peptidomimetic, Pharmaceutical industry

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape.
  • This segment of the report provides insights about the different STAT Inhibitors drugs segregated based on following parameters that define the scope of the report.
  • The companies which have their drug candidate based on STAT Inhibitors in the most advanced stage, i.e.
  • The companies and academics are working to assess challenges and seek opportunities that could influence STAT Inhibitors R&D.

Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis

Retrieved on: 
Donnerstag, Oktober 7, 2021
Health, Managed Care, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Janus, Twitter, Private Securities Litigation Reform Act, JAK2, Forward-looking statement, Diarrhea, Facebook, Inflammation, Health, Therapy, Lupus, Blood, BMY, Caregiver, Juno Therapeutics, Goal, IBD, LinkedIn, Safety, Ulcer, Bristol Myers Squibb, Trial of the century, HIV disease progression rates, Week, Annual report, Cytokine, UC, Instagram, U.S. Securities and Exchange Commission, Sores, Review, Rheumatology, JAK1, Ulcerative colitis, YouTube, JAK3, Mayo, Immune system, Psoriatic arthritis, Multiple sclerosis, Sumathi Best Television Current Reporting Award, Security (finance), Research and Development Council of New Jersey, Dermatology, NYSE, Inflammatory bowel disease, Solution, TYK2, Rectum, Patient, Science, Risk, Psoriasis, Gastroenterology, Research, JAK, Abdominal pain, IFN, Colon, Pharmaceutical industry, Medical imaging, LATTICE-UC, IM011-127, Deucravacitinib, Ulcerative Colitis, Bristol Myers Squibb, LATTICE-UC, IM011-127, DEUCRAVACITINIB, ULCERATIVE COLITIS, BRISTOL MYERS SQUIBB

Bristol Myers Squibb would like to thank the patients and investigators who were involved in the LATTICE-UC clinical trial.

Key Points: 
  • Bristol Myers Squibb would like to thank the patients and investigators who were involved in the LATTICE-UC clinical trial.
  • Bristol Myers Squibb continues to expect greater than $4 billion non-risk adjusted revenue target for deucravacitinib in 2029.
  • LATTICE-UC (IM011-024) is a Phase 2, randomized, placebo-controlled, multicenter study evaluating the safety and efficacy of deucravacitinib in participants with moderate to severe ulcerative colitis (UC).
  • IM011-127 is a Phase 2, randomized, placebo-controlled, multicenter study evaluating the safety, efficacy and biomarker response of deucravacitinib in participants with moderate to severe ulcerative colitis (UC).

Aviceda Therapeutics Announces Additional World-Class Members to its Scientific Advisory Board

Retrieved on: 
Montag, September 20, 2021
Technology, Research, Infectious Diseases, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Therapy, VU University Medical Center, JAK3, List of pathologists, KNAW, Dendrite, ERC, Cell, Royal Netherlands Academy of Arts and Sciences, Harvard Medical School, SCID, Aviceda, Inflammation, Pathology, Coronavirus Scientific Advisory Board (Turkey), Cell biology, IP, Immune system, Cancer research, Science, Amgen, JEM, HIV, COO, GA, UCLA, FIH, CSO, Molecular biology, Ghost, DNA repair, DNA, Geographic atrophy, Government, Autosome, Cancer Research UK, Doctor of Philosophy, College, Government of Northern Ireland, Society, Dendritic cell, College of American Pathologists, DNAR, II, NWO, Cancer, CLIA, Patient, Biomarker, Biology, CLEP, McClay, NIH, PNAS, Pharmaceutical industry, Vaccine, Medicine

Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.

Key Points: 
  • Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.
  • The new additional Aviceda Scientific Advisory Board members includes:
    Aviceda is honored and privileged to add new world-class scientists and renowned researchers to join our efforts in developing the next generation of glyco-immune therapeutics for the treatment of immune-dysfunction conditions, said Mohamed A. Genead, MD, Co-Founder & President of Aviceda Therapeutics.
  • She published more than 280 scientific papers in well recognized journals (Cell, Nature, Nature Immunology, PNAS, and JEM) and supervised 29 PhD students.
  • The Aviceda team is already building on the foundational work in the emerging field of glycobiology to develop potential therapeutics and interventional strategies.

Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients

Retrieved on: 
Mittwoch, September 15, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Janus, Atlas Venture, Hospital, Therapy, TYK2, COPD, Quality of life, Efficiency, PD, Trial of the century, Professor, Inflammation, Patient, Company, Nitric acid, JAK2, Degenerative disease, Atlas, Chronic obstructive pulmonary disease, Disease, JAK1, Safety, JAK, Pharmacokinetics, United Kingdom, PK, Inhalation, Asthma, JAK3, Population, MEU, Lung, Pharmaceutical industry, Severe Asthma, KN-002, Kinaset Therapeutics, Inc., SEVERE ASTHMA, KN-002, KINASET THERAPEUTICS, INC.

Kinaset Therapeutics , a biopharmaceutical company developing a next generation anti-inflammatory therapy to treat patients with severe asthma, today announced that the first 24 participants have been dosed in its Phase 1b placebo-controlled study.

Key Points: 
  • Kinaset Therapeutics , a biopharmaceutical company developing a next generation anti-inflammatory therapy to treat patients with severe asthma, today announced that the first 24 participants have been dosed in its Phase 1b placebo-controlled study.
  • This Phase 1b clinical study is an important step in our goal to develop a new therapy to treat patients with severe asthma regardless of the underlying cause of inflammation, stated Robert Clarke, Ph.D., Chief Executive Officer of Kinaset Therapeutics.
  • Severe asthma affects about 10% of the entire asthma population, impacts quality of life and results in recurrent exacerbations that can lead to hospitalization.
  • Successful completion of this Phase 1b study will enable further investigations in patients with stable moderate to severe asthma and chronic obstructive pulmonary disease (COPD) with outcomes facilitating dose selection for subsequent Phase 2 clinical evaluation.